Business
Adelaide-based pharmaceutical company Mayne Pharma has reported a $92.8 million loss for the 2020 financial year, driven by asset write downs in its generic medicines business.
Business
Mayne Pharma shares have soared 19 per cent to a near five-month high, after the Adelaide-based pharmaceutical company inked an exclusive long-term deal to sell a new contraceptive drug in the United States.
Get InDaily in your inbox. Daily. The best local news sent straight to your inbox every workday at lunchtime.
Thanks for signing up to the InDaily newsletter.
